Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.

Start Date09 Jun 2023

Sponsor / Collaborator

University of Southern California

[+2]

NCT06141356

/ RecruitingNot ApplicableIIT

[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease

[18F]Florbetazine ([18F]92) is a molecularly targeted imaging agent for Aβ protein with a novel diaryl-azine scaffold. It has shown specific binding affinity to Aβ aggregates in postmortem human AD brains and excellent brain pharmacokinetic properties with little non-specific retention in white matter in animal studies and a limited number of patients with Alzheimer's Disease (AD).
The purpose of the current study is to examine the binding properties of [18F]Florbetazine in human subjects and to compare the cortical and white matter binding with [11C]PiB or [18F]Florbetapir in the same subjects.
Imaging of the brain will be completed in healthy adult normal control participants and participants with cognitive impairment (including probable AD and dementia due to other conditions) to characterize [18F]Florbetazine uptake in the brain and its binding properties. [11C]PIB or [18F]Florbetapir PET imaging along with MRI will be completed in the same participants and the data will be compared with 18F-[18F]Florbetazine.

Start Date30 Jan 2023

Sponsor / Collaborator

Peking Union Medical College Hospital

EUCTR2022-002585-33-IT

/ Not yet recruitingPhase 3IIT

A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) - PETAL

Start Date19 Jan 2023

Sponsor / Collaborator

Fondazione Toscana Gabriele Monasterio

100 Clinical Results associated with Florbetaben F-18

100 Translational Medicine associated with Florbetaben F-18

100 Patents (Medical) associated with Florbetaben F-18

215

Literatures (Medical) associated with Florbetaben F-18

01 Dec 2024·Alzheimers & Dementia

Unusually young onset of spastic paraparesis in a carrier of both the A431E PSEN1 and A713T APP variants

Article

Author: Sheikh‐Bahaei, Nasim ; Villareal, Enrique Israel Velazquez ; Ringman, John M ; Islas, Miguel Angel Macias ; Craig, David

Abstract:

Background:

The ways in which diverse genetic variants interact to affect the phenotype of AD is poorly understood. The relatively consistent phenotype associated with specific mutations causing autosomal dominant AD (ADAD) provides the opportunity to study how other genetic variants contribute to disease manifestations.

Method:

We performed an in‐depth case study of a patient with the A431E PSEN1 mutation who had onset of progressive spastic paraplegia at age 20.

Result:

The proband was a Mexican woman known to be at 50% risk for inheriting the A431E PSEN1 mutation that commonly presents with cognitive changes and/or spastic paraplegia at age 40. At age 20 she began developing stiffness in her legs and difficulty walking. When seen at age 26 she had diffuse spasticity worse in the legs, slurred speech, and was cognitively intact. A flortaucipir PET scan at the time was negative as was a florbetaben scan 21 months later despite marked differences from controls in DTI measures in the corticospinal tract. Genetic screening demonstrated the presence of the A431E PSEN1 mutation and an A713T APP variant which was confirmed by WGS. The A713T APP variant was not present in her mother who had more typical disease nor in 62 other persons of Mexican origin.

Conclusion:

The A713T variant in APP has been shown to affect APP processing and Abeta nucleation and is considered to be a risk factor for AD. We hypothesize that the presence of this variant led to the early onset of spastic paraparesis in our proband despite Abeta deposition in brain being undetectable on PET. This finding suggests spastic paraplegia may be related to aberrant APP processing in a manner distinct from plaque formation.This study was funded by R01AG062007 and R01AG069013

01 Dec 2024·Alzheimers & Dementia

The Association between measures of Sleepiness and Subjective Cognitive Decline symptoms in a diverse population of cognitively normal older Adults

Article

Author: Briggs, Anthony Q ; Bernard, Mark A ; Betensky, Rebecca A ; Masurkar, Arjun V.

Abstract:

Background:

Subjective cognitive decline (SCD) is a preclinical stage of Alzheimer’s disease (AD), with correlations to cerebral amyloid and tau and accelerated cognitive decline. Studies have also revealed an association between sleep fragmentation and such AD biomarkers and cognitive decline, suggesting that cognitive function should be monitored in individuals experiencing excessive sleepiness. It is unclear if and how sleep dysfunction relates to SCD apart from AD biomarkers, as well as symptoms related to SCD and sleep dysfunction, such as depression. Furthermore, studies of SCD and sleep dysfunction have primarily focused on non‐Hispanic Whites. Hence, a better understanding of how sleep impacts preclinical AD risk in SCD is needed in more diverse cohorts. We investigated the cross‐sectional relationship between excessive sleepiness in cognitively normal older adults and SCD symptoms linked to cognitive domains in a cohort consisting of NHWs and Black/African Americans (B/AA).

Method:

This retrospective cross‐sectional study included cognitively normal older participants (n = 147, age> 60 years, 61 B/AA, 86 NHW) evaluated at the NYU Alzheimer’s Disease Research Center. Participants underwent Uniform Data Set 3.0 psychometric testing to confirm normal cognition, Epworth Sleepiness Scale (ESS), Geriatric Depression Scale (GDS), and the Cognitive Change Index (CCI) as a measure of SCD. The CCI was further divided into subscores of non‐amnestic (i.e. executive) and amnestic domains (i.e. memory). Participants underwent amyloid (florbetaben) and tau (PI‐2620 or MK‐6240) PET MRI, with composite SUVR calculated by averaging key cortical regions. Multivariable linear regression models tested the association of ESS and covariates (GDS, amyloid SUVR, tau SUVR, race) to the three CCI outcome measures (total, non‐amnestic, amnestic).

Result:

ESS (excessive sleepiness) was significantly positively associated with total CCI (p = 0.01042) as well as non‐amnestic (0.00771) and amnestic CCI subgroups (0.02583), after full covariate adjustment, as was GDS. Race did not show an independent statistically significant association.

Conclusion:

These results suggest that excessive sleepiness, independent of depression and amyloid and tau burdens, may be a significant contributor to SCD severity. Furthermore, these contributions impact both amnestic and non‐amnestic domains. Future studies are needed to investigate the longitudinal impact of excessive sleepiness on SCD outcomes.

07 Nov 2024·PHYSICS IN MEDICINE AND BIOLOGY

PICASSO: a universal brain phantom for positron emission tomography based on the activity painting technique

Article

Author: Cherry, Simon R ; Spencer, Benjamin A ; Huang, Bangyan ; Qi, Jinyi ; Li, Tiantian ; Shanina, Ekaterina

Abstract:

Objective. This study presents a universal phantom for positron emission tomography (PET) that allows arbitrary static and dynamic activity distributions of various complexities to be generated using a single PET acquisition. Approach. We collected a high-statistics dataset (with a total of 22.4 × 109 prompt coincidences and an event density of 2.75 × 106 events mm−3) by raster-scanning a single plane with a 22Na point source mounted on a robotic arm in the field-of-view of the uEXPLORER PET/CT scanner. The source position was determined from the reconstructed dynamic frames. Uniquely, true coincidences were separated from scattered and random events based on the distance between their line-of-response and the known source location. Finally, we randomly sampled the dataset to generate the desired activity distributions modeling several different phantoms. Main results. Overall, the target and the reconstructed phantom images had good agreement. The analysis of a simple geometric distribution showed high quantitative accuracy of the phantom, with mean error of <–3.0% relative to the ground truth for activity concentrations ranging from 5.3 to 47.7 kBq ml−1. The model of a high-resolution 18F-fluorodeoxyglucose distribution in the brain illustrates the usefulness of the technique in simulating realistic static neuroimaging studies. A dynamic 18F-florbetaben study was modeled based on the time-activity curves of a human study and a segmented brain phantom with no coincidences repeating between frames. For all time points, the mean voxel-wise errors ranged from –4.4% to –0.7% in grey matter and from −3.9% to +2.8% in white matter. Significance. The proposed phantom technique is highly flexible and allows modeling of static and dynamic brain PET studies with high quantitative accuracy. It overcomes several key limitations of the existing phantoms and has many promising applications for the purposes of image reconstruction, data correction methods, and system performance evaluation, particularly for new high-performance dedicated brain PET scanners.

News (Medical) associated with Florbetaben F-18

11 Feb 2025

·www.drugs.com

NIH-Funded Clinical Trial Will Evaluate New Dengue Therapeutic

February 11, 2025 -- A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease. The study is supported by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), and will involve exposing adult volunteers to a weakened strain of dengue virus that causes a mild form of the disease and administering an investigational therapeutic at various doses to assess its safety and ability to lessen symptoms. Dengue is transmitted via infected Aedes mosquitoes and sickens as many as 400 million people each year, primarily in tropical and subtropical parts of the world, according to the U.S. Centers for Disease Control and Prevention. In 2024, dengue cases surged to record levels in the Americas with local U.S. transmission reported in Arizona, California, Florida, Hawaii, and Texas. Dengue is endemic in Puerto Rico, which reported nearly 1,500 cases last year. Most people with dengue do not develop symptoms, but those who do commonly experience severe headache and body aches, nausea and vomiting, fever and rash. One in 20 people who get sick with dengue progress to severe illness, which may lead to shock, internal bleeding, and death. There is currently no Food and Drug Administration-approved treatment for dengue. “When caring for a patient who is critically ill with dengue, healthcare providers have few options other than providing supportive care,” said NIAID Director Jeanne Marrazzo, M.D., M.P.H. “We must find safe and effective therapeutics to provide much-needed relief to people suffering from dengue.” The new clinical trial will test the ability of AV-1, an investigational human monoclonal antibody therapeutic developed by AbViro (Bethesda, Maryland), to mitigate clinical symptoms when administered before and after dengue virus infection. The results of a previously completed NIAID-supported Phase 1 trial indicated that AV-1 is safe in humans, providing the basis for the new clinical trial to test its safety and efficacy. The Phase 2 clinical trial will enroll at least 84 healthy adult volunteers at two sites: the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research in Baltimore, and the University of Vermont Vaccine Testing Center in Burlington. Following an initial screening and physical examination, volunteers will be randomly assigned to one of two groups. One group will receive AV-1 one day prior to being challenged with a mild strain of dengue virus, and the other will receive AV-1 four days after being challenged with the dengue virus. Each group will be further subdivided to receive 100 mg, 300 mg, or 900 mg of AV-1, delivered in a 60-minute intravenous infusion. For each of the three dosage levels, 12 participants will receive the investigational monoclonal antibody, and two will receive a placebo. Before or after AV-1 dosing, each volunteer will receive an injection of attenuated (weakened) dengue virus. In earlier studies using this challenge virus, most volunteers developed a rash, and some had other mild dengue symptoms, such as joint and muscle pain or headache. None of the volunteers developed dengue fever or severe dengue. Volunteers will participate in regular follow-up visits with study staff for at least 155 days to carefully monitor the effects of the investigational monoclonal antibody. Through physical exams, diary cards and blood samples, researchers will document how the volunteers’ immune systems respond to the dengue virus challenge, how quickly the virus vanishes from their bloodstream and any symptoms they may experience. The researchers will use this information to determine how AV-1 affects the volunteers’ ability to recover from dengue compared to placebo and to determine the dosages at which AV-1 may be effective. If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and efficacy against dengue virus. For more information about the study, visit ClinicalTrials.gov and search the identifier NCT05048875. NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. Source: NIH Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Phase 2Vaccine

21 Jan 2025

·www.prnewswire.com

Life Molecular Imaging Secures FDA Fast Track Designation for [18F]Florbetaben in Diagnosing Cardiac AL and ATTR Amyloidosis

[18F]florbetaben has been granted a Fast Track designation for cardiac amyloidosis, which will expedite the development of [18F]florbetaben for this indication [18F]florbetaben previously received orphan drug status as a diagnostic for the management of AL amyloidosis in EU and US The efficacy of [18F]florbetaben in diagnosing cardiac amyloidosis is being evaluated in an ongoing multi-center Phase 3 study BOSTON, Jan. 21, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), an international pharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to [18F]florbetaben for the diagnosis of cardiac amyloid light-chain (AL) and amyloid transthyretin-related (ATTR) amyloidosis. Fast Track is an FDA process designed to facilitate the development and expeditious evaluation of drugs which are used to treat serious conditions and fill an unmet medical need. The purpose of Fast Track is to get important new drugs to patients earlier. [18F]florbetaben PET is validated and approved to detect neuritic beta amyloid plaques in the brain and is available via a global supply network marketed as Neuraceq®. [18F]florbetaben has demonstrated its capability to identify amyloid deposits in the heart, including AL and ATTR. These findings led to its Orphan Drug Designation by both the European Commission and the FDA in 2020 for diagnosis of AL amyloidosis. The current Phase 3 trial (NCT05184088) aims to further validate [18F]florbetaben's efficacy in the diagnosis of cardiac amyloidosis. "The FDA's Fast Track Designation is a pivotal achievement that highlights the potential of [18F]Florbetaben to address a critical gap in diagnosing cardiac AL and ATTR amyloidosis", said Dr. Ludger Dinkelborg, CEO of Life Molecular Imaging. "Diagnosing cardiac AL amyloidosis is complex and challenging", added Dr. Andrew Stephens, MD, PhD, CMO of Life Molecular Imaging. "[18F]florbetaben PET imaging of patients with suspected cardiac amyloidosis has the potential to streamline the diagnostic process, providing earlier and appropriate access to therapy and improved monitoring of such interventions." About [18F]florbetaben Neuraceq® ([18F]florbetaben) is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. Neuraceq has been approved for routine clinical use in this indication by FDA, EMA and MHRA, and has local regulatory approval in other countries such as Canada, UK, Japan, China, Taiwan, and Korea. [18F]florbetaben is currently under investigation as a targeted radiopharmaceutical for the detection of amyloid deposits in the heart and other organs of patients with cardiac and systemic amyloidosis of AL and ATTR type. Most Common Adverse Reactions In clinical trials including demented and non-demented subjects, the most frequently observed adverse drug reactions in 872 subjects with 1090 Florbetaben (18F) administrations were injection/application site erythema (1.7%), injection site irritation (1.1%), and injection site pain (3.4%). About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI) is an international radiopharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit . About Life Healthcare Group Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 40 years' experience in the South African private healthcare sector, and currently operates 64 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, oncology, diagnostic and molecular imaging and health risk management services which include occupational health and wellness services. The Group also owns Life Molecular Imaging, a radiopharmaceutical business dedicated to developing and globally commercializing innovative molecular imaging agents for use in PET-CT diagnostics to detect specific diseases. Visit: . For media queries Brittany Hahn | Marketing Communications Manager | Life Molecular Imaging Tel: +1.484.735.2840 | [email protected] SOURCE Life Molecular Imaging WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Fast TrackOrphan DrugDrug Approval

13 Jan 2025

·endpts.com

Lantheus to buy Life Molecular Imaging for $350M, netting Alzheimer's diagnostic

Radiopharmaceutical maker Lantheus Holdings plans to acquire Life Molecular Imaging for $350 million in a bid to build up its commercial Alzheimer’s diagnostics business. In addition to the $350 million upfront payment, the deal includes up to $400 million in potential earnout and milestone payments. Six months ago, Lantheus made a deal with Life Molecular Imaging to license a diagnostic and therapeutics pair of radiopharmaceuticals, both of which target a protein called gastrin-releasing peptide receptor that’s highly expressed in breast and prostate cancer. Lantheus’ top-selling drug is a radioactive agent used to diagnose prostate cancer called Pylarify. Lantheus is gaining five assets from the buyout, namely a commercial Alzheimer’s diagnostic agent called Neuraceq. It’s an area that Lantheus has been investing in, though previous acquisitions were for experimental agents. In July, Lantheus bought Meilleur Technologies and its experimental beta amyloid PET imaging agent called NAV-4694. In 2023, Lantheus bought Cerveau Technologies for its experimental tau-targeted PET imaging agent known as MK-6240. “This puts us squarely in the Alzheimer’s space a whole lot earlier — at least a year earlier — than we were planning with the launch of [MK-6240], and we’ve got a ready-[to]-go franchise,” CEO Brian Markison said.

AcquisitionDiagnostic Reagents

100 Deals associated with Florbetaben F-18

External Link

KEGG	Wiki	ATC	Drug Bank
-	Florbetaben F-18	V09AX06	DB09148

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alzheimer Disease	US	Life Molecular Imaging Ltd.	19 Mar 2014
Cognitive Dysfunction	EU	Life Molecular Imaging Ltd.	20 Feb 2014
Cognitive Dysfunction	IS	Life Molecular Imaging Ltd.	20 Feb 2014
Cognitive Dysfunction	LI	Life Molecular Imaging Ltd.	20 Feb 2014
Cognitive Dysfunction	NO	Life Molecular Imaging Ltd.	20 Feb 2014
Diagnostic agents	EU	Life Molecular Imaging Ltd.	20 Feb 2014
Diagnostic agents	IS	Life Molecular Imaging Ltd.	20 Feb 2014
Diagnostic agents	LI	Life Molecular Imaging Ltd.	20 Feb 2014
Diagnostic agents	NO	Life Molecular Imaging Ltd.	20 Feb 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Immunoglobulin Light-Chain Amyloidosis	Phase 3	US	Life Molecular Imaging Ltd.	13 Jan 2023
Immunoglobulin Light-Chain Amyloidosis	Phase 3	DE	Life Molecular Imaging Ltd.	13 Jan 2023
Immunoglobulin Light-Chain Amyloidosis	Phase 3	ES	Life Molecular Imaging Ltd.	13 Jan 2023
Immunoglobulin Light-Chain Amyloidosis	Phase 3	GB	Life Molecular Imaging Ltd.	13 Jan 2023
Senile cardiac amyloidosis	Phase 3	US	Life Molecular Imaging Ltd.	13 Jan 2023
Senile cardiac amyloidosis	Phase 3	DE	Life Molecular Imaging Ltd.	13 Jan 2023
Senile cardiac amyloidosis	Phase 3	ES	Life Molecular Imaging Ltd.	13 Jan 2023
Senile cardiac amyloidosis	Phase 3	GB	Life Molecular Imaging Ltd.	13 Jan 2023
Transthyretin cardiac amyloidosis	Phase 3	US	Life Molecular Imaging Ltd.	13 Jan 2023
Transthyretin cardiac amyloidosis	Phase 3	DE	Life Molecular Imaging Ltd.	13 Jan 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01222351 (CTgov)	Not Applicable	Alzheimer Disease \| Cognitive Dysfunction	161	BAY 94-9172 (Florbetaben)	iagortcjtq(ozaoqreiaj) = uoohwekihz xpsttniwpr (nxylldjefv, wczjdlgjsc - yxhvegvoqw) View more	-	06 May 2024
NCT03744312 (CTgov)	Phase 1/2	Alzheimer Disease \| Inflammation	9	Florbetaben+11C-ER176 (Cognitive Impairment)	acdgubrmss(gdobobxkei) = myifrawoug njciubnqxy (jpbqvhyuxp, girkdexgfb - srlzerfczg) View more	-	13 Sep 2023
				Florbetaben+11C-ER176 (No Cognitive Impairment)	acdgubrmss(gdobobxkei) = svddmhrcpw njciubnqxy (jpbqvhyuxp, zslumriicq - zqlrwdxbcl) View more
SNMMI2023	Not Applicable	Alzheimer Disease	-	18F-Florbetaben (18F-FBB)	auszyiusqe(kffzwqttbl) = brrknahxnl pfxfoihfhi (axnqczrfjq, > - 1.585) View more	-	28 Aug 2023
AMYPAD Diagnostic and Patient Management Study (EANM2022)	Not Applicable	Memory Disorders amyloid burden	729	18f-florbetaben (FBB)	ewyookfknb(myucampkhk) = ndsxnhmbwl psmkbwzawz (mquppriveo, 17.87) View more	-	22 Sep 2022
				18f-flutemetamol (FTM)	ewyookfknb(myucampkhk) = vxotvikuww psmkbwzawz (mquppriveo, 17.87) View more
EANM2021	Not Applicable	Plaque, Amyloid \| Periodontitis	-	18 F-Florbetaben (Absence of periodontal disease or mild periodontitis)	uzoaanasum(tcgzhutdxc) = qiufzdldnl ugkjrblade (nbswfqsgqo )	-	24 Sep 2021
SNMMI2021	Not Applicable	Alzheimer Disease amyloid	264	F18-Florbetaben (Early phase FBB (eFBB))	elsclcvsmb(pjrhkdgwky) = jtgvvaogzz medrxugamd (lrvqyplgbr )	Positive	18 May 2021
				F18-Florbetaben (Delay-phase FBB (dFBB))	elsclcvsmb(pjrhkdgwky) = hwrniqwuhf medrxugamd (lrvqyplgbr )
SNMMI2020	Not Applicable	Plaque, Amyloid	-	18 F-Florbetaben (Young Healthy Controls (YHC))	wfbbdortcs(thoyvctxkw) = qdnthawuuu wohjvgabiq (ucenleyndt, 0.03)	-	15 May 2020
				18 F-Florbetaben (Subjective Cognitive Decline (SCD))	aelqjjnnvw(jlgydswclg) = mrymdntbtj iwuuehxktd (zhqloyrdkx, 2.1) View more
EANM2019	Not Applicable	Peroxisomal Disorders gene defect \| very long chain fatty acids (VLVFA)	4	[18F]Florbetaben (X-linked adulthood cerebral adrenoleukodystrophy (X-ACALD) patients)	pxmhajavee(vvzoxllpde) = 9.8 ± 2.6 ddykaxagfw (mqdaogdjta ) View more	-	18 Sep 2019
				[18F]Florbetaben (Healthy control group)
EANM2019	Not Applicable	-	6	[18F]Florbetaben (Standard PET images)	zwsrqxckqk(wufetudyul) = enboavlzjq hgviaxexmd (rcgusulbup ) View more	-	18 Sep 2019
				[18F]Florbetaben (PET images with superimposed WM/GM boundaries)	wnqgoiusac(rzpibseglp) = oxnttrlrfr cdeqpsbexc (tpwgkhvqtx ) View more
EANM2018	Not Applicable	-	44	18F-Florbetaben (Amyloid-PET)	walaufbepa(xzgjdhbrlb) = sknlnlfnsn wmrelohydt (efkhxnawbd )	Positive	18 Sep 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis